Short Interest in Onconetix, Inc. (NASDAQ:ONCO) Rises By 60.5%

Posted by on Aug 18th, 2026

Onconetix, Inc. (NASDAQ:ONCO – Get Free Report) was the target of a significant increase in short interest during the month of July. As of July 31st, there was short interest totaling 196,172 shares, an increase of 60.5% from the July 15th total of 122,244 shares. Approximately 17.3% of the company’s stock are sold short. Based on an average daily trading volume, of 360,996 shares, the days-to-cover ratio is currently 0.5 days.

Onconetix Stock Performance

ONCO stock traded down $0.01 on Tuesday, hitting $0.75. 735,723 shares of the company’s stock were exchanged, compared to its average volume of 677,666. Onconetix has a 12-month low of $0.67 and a 12-month high of $209.50. The firm has a 50 day moving average price of $0.93 and a two-hundred day moving average price of $15.66. The stock has a market cap of $855,342.00, a P/E ratio of 0.00 and a beta of 2.69.

Onconetix (NASDAQ:ONCO – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.28) EPS for the quarter, beating analysts’ consensus estimates of ($4,505.00) by $4,503.72. Onconetix had a negative return on equity of 91.95% and a negative net margin of 1,575.89%.The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ONCO. Wall Street Zen raised shares of Onconetix from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings cut shares of Onconetix from a “sell (e+)” rating to a “sell (e)” rating in a research report on Tuesday, August 11th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Onconetix has an average rating of “Sell”.

Get Our Latest Report on Onconetix

Institutional Trading of Onconetix

A hedge fund recently bought a new stake in Onconetix stock. Citadel Advisors LLC bought a new position in shares of Onconetix, Inc. (NASDAQ:ONCO – Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 15,633 shares of the company’s stock, valued at approximately $49,000. Citadel Advisors LLC owned about 1.00% of Onconetix at the end of the most recent quarter. 23.89% of the stock is owned by institutional investors.

About Onconetix

(Get Free Report)

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

Featured Stories

Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.